Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

CORT

CORCEPT THERAPEUTICS INC

Pharmaceutical Preparations · SIC 2834CIK 1088856Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$761.0M
Net Income FY2025
$100.0M
EPS (Basic, as reported)
$0.95
Net Margin FY2025
13.1%
ROE FY2025
15.4%
Total Equity
$648.0M
Shares Out
108M
Business description

CORCEPT THERAPEUTICS INC — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2000–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 81 → 761 +28.3% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue81159251306354366402482675761
Cost of revenue(2)(4)(5)(6)(6)(5)(5)(6)(11)(13)
Research & development(24)(40)(75)(89)(115)(114)(131)(184)(247)(255)
Selling, general & administrative(45)(62)(81)(100)(105)(122)(153)(184)(280)(449)
General & administrative——————————
Total operating expenses(71)(106)(162)(195)(226)(242)(289)(375)(538)(717)
Operating income10538911212812411310713745
Interest expense(2)—————————
Other income (expense), net—————14172522
Pre-tax income8539211713212511612516166
Income tax expense0(76)(17)(22)(26)(12)(15)(18)(20)(33)
Net income81297594106113101106141100
EPS — basic$0.07$1.14$0.65$0.82$0.92$0.97$0.95$1.02$1.35$0.95
EPS — diluted$0.07$1.04$0.60$0.77$0.85$0.89$0.87$0.94$1.23$0.82
Shares outstanding — basic (M)111114115114115116107104103104
Shares outstanding — diluted (M)116125127123124126116112113120

Showing the latest 10 of 26 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.